Fishing the targets of myeloid malignancies in the era of next generation sequencing

详细信息    查看全文

• 作者：Xiangguo Shi¹ ; ^{sxg_njmu@163.com" class="auth_mail" title="E-mail the corresponding author} ; Bai-Liang He¹ ; ^{bailiang.he@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Alvin C.H. Ma ^{alvinma@hku.hk" class="auth_mail" title="E-mail the corresponding author} ; Anskar Y.H. Leung ; ^{ayhleung@hku.hk" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Zebrafish ; Next generation sequencing ; Gene mutations ; TALEN ; CRISPR/Cas9
• 刊名：Blood Reviews
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：30
• 期：2
• 页码：119-130
• 全文大小：1829 K

文摘

Recent advent in next generation sequencing (NGS) and bioinformatics has generated an unprecedented amount of genetic information in myeloid malignancies. This information may shed lights to the pathogenesis, diagnosis and prognostication of these diseases and provide potential targets for therapeutic intervention. However, the rapid emergence of genetic information will quickly outpace their functional validation by conventional laboratory platforms. Foundational knowledge about zebrafish hematopoiesis accumulated over the past two decades and novel genome editing technologies and research strategies in this model organism have made it a unique and timely research tool for the study of human blood diseases. Recent studies modeling human myeloid malignancies in zebrafish have also highlighted the technical feasibility and clinical relevance of these models. Careful validation of experimental protocols and standardization among laboratories will further enhance the application of zebrafish in the scientific communities and provide important insights to the personalized treatment of myeloid malignancies.